Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of sintilimab combined with chemoradiotherapy for stage IV cervical cancer
ChiCTR2100045676Phase 2Recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in Cervical Cancer (CC), sponsored by Anhui Provincial Tumor Hospital. Primary endpoints: Progression-free survival, Overall survival and 1 more. Started Jun 2021; status: recruiting.
02
Drugs
sintilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2100045676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045676.